Compare WY & BAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WY | BAX |
|---|---|---|
| Founded | 1900 | 1931 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3B | 13.9B |
| IPO Year | 1994 | 1994 |
| Metric | WY | BAX |
|---|---|---|
| Price | $18.59 | $23.64 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 13 |
| Target Price | ★ $31.00 | $28.73 |
| AVG Volume (30 Days) | 5.3M | ★ 5.7M |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | ★ 4.41% | 0.17% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.44 | 0.21 |
| Revenue | $6,905,000,000.00 | ★ $11,244,000,000.00 |
| Revenue This Year | $4.39 | $3.32 |
| Revenue Next Year | $7.66 | $2.12 |
| P/E Ratio | ★ $44.35 | $111.38 |
| Revenue Growth | N/A | ★ 5.72 |
| 52 Week Low | $19.50 | $15.73 |
| 52 Week High | $27.75 | $30.00 |
| Indicator | WY | BAX |
|---|---|---|
| Relative Strength Index (RSI) | 16.73 | 45.44 |
| Support Level | N/A | $22.56 |
| Resistance Level | $25.14 | $24.30 |
| Average True Range (ATR) | 0.50 | 0.62 |
| MACD | -0.21 | 0.07 |
| Stochastic Oscillator | 0.14 | 72.41 |
Weyerhaeuser Co ranks among the world's key forest product companies. Following the 2016 sale of its pulp business to International Paper, Weyerhaeuser operates three business segments: timberlands, wood products, and real estate. Weyerhaeuser is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities. Earnings from its wood products segment are subject to federal income tax. Weyerhaeuser acquired fellow timber REIT Plum Creek in 2016.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.